Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.

Taylor, Stephen, Jayasuriya, Ashini, Fisher, Martin, Allan, Sris, Wilkins, Ed, Gilleran, Gerry, Heald, Lisa, Fidler, Sarah, Owen, Andrew, Back, David and Smit, Erasmus (2012) Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. The Journal of antimicrobial chemotherapy, 67 (3). pp. 675-80. ISSN 1460-2091.

Full text not available from this repository. (Request a copy)
Official URL: http://jac.oxfordjournals.org/content/67/3/675.lon...

Abstract

Plasma efavirenz concentrations can persist up to 3 weeks after patients stop efavirenz-containing regimens. This suggests a strategy of stopping efavirenz only 1 week before NRTIs may not be long enough for some individuals. The use of lopinavir/ritonavir monotherapy for a 4 week period may be an alternative pharmacologically and virologically effective universal stopping strategy which warrants further investigation.

Item Type: Article
Subjects: WC Communicabable diseases
Divisions: Clinical Support > Infectious Diseases
Depositing User: Users 7 not found.
Date Deposited: 10 Jun 2014 13:42
Last Modified: 10 Jun 2014 13:42
URI: http://www.repository.uhblibrary.co.uk/id/eprint/126

Actions (login required)

View Item View Item